New pill aims to curb focal seizures in adults

NCT ID NCT07594119

Recruiting now Disease control Sponsor: Rapport Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 3 times

Summary

This phase 3 study tests whether an investigational drug called RAP-219 can safely reduce the number of focal seizures in adults with epilepsy. About 312 participants will take either a low or medium dose of RAP-219 or a placebo pill daily. The main goal is to see if the drug lowers seizure frequency compared to a placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RAP-219 (an oral drug taken daily)
What this could lead to: If successful, RAP-219 could offer a new daily medication option to help people with focal seizures have fewer seizures.
What could go wrong: This is a phase 3 trial, but the drug is still investigational. It may not work better than placebo, and side effects are possible. Results may not apply to all epilepsy types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPILEPSY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

epilepsy focal epilepsy visual epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPILEPSY FOCAL EPILEPSY FOCAL SEIZURE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Colorado Springs Neurological Associates
RECRUITING

Colorado Springs, Colorado, 80919, United States
K2 Medical Research
RECRUITING

Maitland, Florida, 32751, United States
Pillar Clinical Research
RECRUITING

Bentonville, Arkansas, 72712, United States
University of Texas Health Science Center in Houston
RECRUITING

Houston, Texas, 77030, United States
Velocity Clinical Research
RECRUITING

Raleigh, North Carolina, 27607, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.